Clinical Trials Logo

Clinical Trial Summary

Malignant biliary obstruction commonly caused by pancreatic adenocarcinoma, cholangiocarcinoma and other etiologies like gallbladder carcinoma, hepatocellular carcinoma, lymphoma, and metastasis to regional solid organs and lymph nodes. Pancreatobiliary cancers generally present with jaundice, weight loss, and anorexia with significant impact on quality of life, morbidity, and mortality. The primary goal of diagnosis and management is curative resection but it's difficult due to local invasion and distant metastases at the time of clinical presentation. Biliary decompression helps to reduce symptoms and improve quality of life in patients with malignant biliary obstruction. Endoscopically placed stents have become the standard of care for non-surgical biliary drainage due to their minimal invasiveness compared to percutaneous drainage. The standard treatment of obstructive jaundice has been ERCP with biliary stent placement with high success rate in expert hands and low frequency of adverse events. Endoscopic ultrasound-guided biliary drainage (EUS-BD) has been increasingly used in patients who underwent failed ERCP. EUS-BD can be performed in several ways, choledochoduodenostomy (CDS), hepaticogastrostomy (HGS), antegrade (AG) procedure, and rendezvous (RV) technique.


Clinical Trial Description

This study will be a single center, prospective randomized comparative study that includes 50 patients with distal malignant biliary obstruction including pancreatic head masses, distal cholangiocarcinoma or papillary carcinoma. All patients with inclusion criteria will be recruited in the study by simple random sampling using sealed envelopes until fulfillment of needed sample size for both EUS-BD arm and ERCP-BD arm. Study tools: - Informed consent will be obtained from each participant sharing in the study. - Throughout history taking, complete general examination and local abdominal examination. - Laboratory investigations: CBC, Serum creatinine, Liver functions tests (AST, ALT and Serum Albumin), Alkaline phosphatase, Serum bilirubin and INR. - ERCP-BD by papillary approach and EUS-BD by choledochoduodenostomy with transmural stent placement. - All procedures will be performed under deep sedation or general anesthesia in the left lateral position. - Procedural time is recorded. - Technical success is considered after stent placement (expanded and patent) with good bile flow and drainage. - Follow up: - Lab investigations will be requested at 2 days, 2 and 4 weeks, 3 and 6 months after the procedure including: CBC, S.Cr, S.Bil, AST, ALT, S.Alb, ALP and INR. - Early adverse events (within 48 hours after procedure) including: Pancreatitis, Cholangitis, Bleeding, Perforation and Peritonitis. - Late adverse events include stent dysfunction either due to food impaction, tumor ingrowth or stent migration. - Clinical success is considered at 2 weeks if total bilirubin is less than 50% of baseline and at 4 weeks if total bilirubin is less than 3mg/dL. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04898777
Study type Interventional
Source Mansoura University
Contact Ahmed M Gaheen, MSc.
Phone +201220755170
Email gaheen@gmail.com
Status Recruiting
Phase N/A
Start date July 1, 2021
Completion date July 1, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT04941924 - The ID- RFA Trial: A Trial of Intraductal Radio-frequency Ablation (ID-RFA) Plus Biliary Stenting Versus Biliary Stenting Alone for the Treatment of Malignant Biliary Obstruction. N/A
Active, not recruiting NCT03672019 - A Quality of Life Study in Patients Undergoing Percutaneous Biliary Drainage
Recruiting NCT05220475 - A Comparison of a Fully Covered Self-expandable Metal Stent With an External Anchoring Plastic Stent and Uncovered Stent N/A
Completed NCT02001779 - IRS(Irradiation Stent) vs. CS(Conventional Stent) Insertion in Inoperable Malignant Biliary Obstruction N/A
Not yet recruiting NCT06375928 - EUS-guided Choledochoduodenostomy vs ERCP as First Line in Malignant Distal Obstruction in Resectable Disease (CARPEDIEM-1 Trial) N/A
Not yet recruiting NCT06375954 - EUS-guided CDS vs ERCP as First Line in Malignant Distal Obstruction in Borderline Disease (CARPEDIEM-2 Trial) N/A
Recruiting NCT05786326 - Multihole Fully Covered Metallic Stents in the Management of Malignant Biliary Obstruction N/A
Not yet recruiting NCT06375967 - EUS-Gallbladder vs CDS as First Line in MBDO- Palliative (CARPEGIEM Trial) N/A
Completed NCT01869894 - A Prospective Randomized Study for Efficacy of Uncovered Double Bare Metallic Stent Compared to Uncovered Single Bare Metallic Stent in Malignant Biliary Obstruction N/A
Not yet recruiting NCT05804201 - EUS-guided Hepatico-gastrostomy With Hot Giobor N/A
Recruiting NCT01686425 - Percutaneous Transhepatic Cholangiography Versus Endoscopic Ultrasound Guided Biliary Drainage N/A
Recruiting NCT03215108 - Comparison Between Novel Flower-type Covered Stent and Conventional Covered Stent N/A
Recruiting NCT05169398 - EUS-guided Hepatico-gastrostomy Using a Novel Lumen Apposing Metal Stent N/A
Enrolling by invitation NCT05233293 - Spyglass+RFA Versus Cytobrush+RFA for Extrahepatic Cholangiocarcinoma N/A
Completed NCT03812250 - EUS-guided Biliary Drainage vs. ERCP Assisted Transpapillary Drainage for Malignant Biliary Obstruction N/A
Completed NCT03000855 - EUS - Guided Choledocho-duodenostomy Versus ERCP With Covered Metallic Stents in Patients With Unresectable Malignant Distal Common Bile Duct Strictures Phase 2/Phase 3
Recruiting NCT01073514 - Clinical Trial of Bile Etiology ,Proteomics and Metabonomics of Malignant Biliary Obstruction N/A
Recruiting NCT05142839 - Palliation of Gastric Outflow Obstruction in Case of Concomitant Biliary Obstruction. N/A
Recruiting NCT05729867 - Efficacy and Safety of a Fully Covered Self-Expandable Metal Stent for Unresectable HCC N/A
Completed NCT04405752 - Evaluation of a New Metal Biliary Stent of 12-mm Diameter: a Case Control Study